Post Reply
381-400 of 828
If you base on the price paid by the top major shareholder who paid 52 cts per share for some 71.46 million shares in Nov 2021, the offer price shall be at least 52 cts.
Should be low ball offer.. they halt to prevent the price from overshooting their offer price.
0.60 offer . Can delist
Hope that if it is an offer, it is not a low ball one.
and hope that the announcement is not about some non-material matters such as getting some gloabl awards and recognition etc
and hope that the announcement is not about some non-material matters such as getting some gloabl awards and recognition etc
Halted 2-3 days already.
It is my observation that when halt is over several days, takeover quite
likely.
It is my observation that when halt is over several days, takeover quite
likely.
Take so long to give any announcement. I think could be a complex transaction still in the making.
lsk007 ( Date: 23-Jun-2023 08:54) Posted:
|
Rights issues?
ahberngh ( Date: 22-Jun-2023 09:05) Posted:
|
Possible low ball takeover offer???
Nice juicy meal for vultures???
Nice juicy meal for vultures???
Requested for trading halt before the market close. The last done price of 41.5 cts is still very much below the price (52 cts) which the top major shareholder paid to acquire 71,460,300 shares in Nov 2021.
Trading halt. What is going on? What announcement?
ValueSeer ( Date: 16-Jun-2023 16:32) Posted:
|
Net cash of cordlife is almost $80mil against current market cap of $100mil. Business is net cash flow positive so cash will keep going up. When net cash chases towards market cap, this may create a floor for the price. Price seems to be trending higher in recent days , looks like people are finding value in this stock.
Results should be better than 2022 since restrictions ended somewhere in 2022 and expo / baby shows are coming back which means more net cash as the company acquires more customers
PRESS RELEASE
Cordlife delivers highest Q1 net profit since 2021 with a year-on-year increase of 19.7% to S$1.2 million
&bull Revenue for 1Q2023 increased by 8.4% year-on-year (" yoy" ) to S$14.1 million with the banking business enjoying the benefits of a return to in-person marketing events &bull Net profit margin improved by 0.8 percentage points (" pp" ) to 8.2% while gross profit edged up 0.3pp to 67.5% with improved economies of scale
&bull Moving forward, the Group will continue to invest in its marketing initiatives as momentum picks up for large scale events and in-person opportunities.
Cordlife delivers highest Q1 net profit since 2021 with a year-on-year increase of 19.7% to S$1.2 million
&bull Revenue for 1Q2023 increased by 8.4% year-on-year (" yoy" ) to S$14.1 million with the banking business enjoying the benefits of a return to in-person marketing events &bull Net profit margin improved by 0.8 percentage points (" pp" ) to 8.2% while gross profit edged up 0.3pp to 67.5% with improved economies of scale
&bull Moving forward, the Group will continue to invest in its marketing initiatives as momentum picks up for large scale events and in-person opportunities.
Good results but no dividend. Seems like the first time not giving dividend
Cordlife records growth in revenue to S$29.4 million in 2H2021 amid
another challenging year of COVID-19 disruptions
-Revenue for 2H2021 increased year-on-year as number of new samples stored and processed as
well as uptake in diagnostics services continue to show recovery and growth.
- Despite pressure on profitability due to COVID-19 induced challenges, gross profit margin has
continued to grow with efficient cost-saving measures.
-The Group proposed a final dividend of 0.9 Singapore cents per ordinary share, representing a
payout ratio of 37.42% of net profit after tax for FY2021.
- Moving forward, the Group will continue to ramp up its digital initiatives and expand its product
offerings while continuing to monitor the market to identify opportunities for expansion.....
https://links.sgx.com/1.0.0/corporate-announcements/CL6QPJ1471Y0YKO9/703892_Cordlife_FY2021_Press_Release.pdf
https://edition.cnn.com/2022/02/15/health/hiv-third-person-remission/index.html
Researchers report third case of HIV remission after stem cell transplant using umbilical cord blood. Huge potential! Expect price to surge eventually.
Researchers report third case of HIV remission after stem cell transplant using umbilical cord blood. Huge potential! Expect price to surge eventually.
Joelton ( Date: 01-Dec-2021 10:00) Posted:
|
New shareholder may be what' s needed to inject ' new blood' into Cordlife' s anaemic trajectory
LET' S face it - Cordlife Group is long overdue for a reset. The mainboard-listed cord blood banking and family diagnostic services provider has done nothing remarkable in recent years - except to survive.
Its one big hurrah was six years ago, when it sold its shares and convertible notes in China Cord Blood Corp - mainland China' s first and largest cord blood group - and pocketed handsome gains, sharing the sweetness with shareholders in the form of a special dividend of S$0.13 per share.
The company' s much-trumpeted goal to expand in South-east Asia has come to little. And the controversial exit of its long-serving chief executive Jeremy Yee, which revealed cracks in the company' s board and management, has not helped. India, a market it had banked on and where it had splurged on marketing to bring in big volumes, took more than it gave back.
Revenue has more or less flatlined in recent years while its earnings trajectory has been nothing to shout about. And its reputation as a dividend slouch still persists. Going by its 9-month showing, this year is working out to be little different.
In other words, the investing story for this healthcare services stock with a market value of some S$102 million is flat out dull. The stock is down nearly 4 per cent this year, and trades at 15.3 times - versus the average of 21 times among peers in the region.
Change in the air
There is, however, a whiff of change in the air. Three married deals were done recently involving a big chunk of its shares, driving the stock to a two-year high of S$0.49 on Nov 10 - up 15 per cent from the day before.
Filings later in the day revealed that TransGlobal Real Estate Group, whose voting rights are equally held by Lui Yim Sheung and Yiu Chi Shing, has emerged with a 27.99 per cent stake in Cordlife. Yiu is chairman of TransGlobal Group (International), which is principally engaged in real estate development and operation, as well as financial investments and infrastructure in Hong Kong and mainland China.
Yiu has since installed his son as a a non-independent non-executive director. Cordlife announced on Tuesday (Nov 30) that Yiu Chi Shing will join the board effective Wednesday.
TransGlobal paid S$37.2 million or S$0.52 a piece - a 22.4 per cent premium over Cordlife' s previous day' s close - to acquire the block from Cordlife' s previous controlling owner Hon Kwok Lung, a Hong Kong tycoon.
Hon' s exit from Cordlife comes three years (short of four days) since he first emerged in the picture. He first scooped up a 21.5 per cent stake in Cordlife from its majority owner China Construction Bank Corp and paid S$25 million or S$0.45 apiece.
Less than a year later, he raised his stake to nearly 28 per cent - coughing up S$10 million for the additional shares. Interestingly, the self-made tycoon, who made it to Forbes' Billionaires 2018 list, took this bigger bite of Cordlife just about a month after the company had lobbed a proposal in June 2019 to merge its business with New York-listed Global Cord Blood Corporation (GCBC), which was formerly called China Cord Blood Corp. The deal, potentially worth S$1.3 billion and deemed a game changer for Cordlife, flopped in February this year with both parties deciding to bow out from talks.
The timing of Hon' s exit could suggest that sans this sizeable M& A play, his interest in Cordlife had waned.
But he may not be the only one disappointed.
Cordlife' s second largest shareholder Nanjing Xinjiekou Department Store, a Shanghai-listed retail giant, had also bought into the company five years ago, describing the acquisition as one aimed to " aid" Cordlife' s expansion into the cord blood business in South-east Asia. But very little has happened on this front.
What now?
Inorganic expansion has long been a vaunted goal for this once-upon-a-time growth stock. For what seems like forever, Cordlife has said it wants to enlarge its geographical footprint, introduce new consumer healthcare products and forge collaborative networks and strategic alliances. It has also been seeking to expand its mother and child segment.
The " buy and build strategy" is in fact an imperative for Cordlife, which has been facing rising competition in Singapore, chiefly from public cord blood banking, and low fertility rates.
Cordlife also has operations in Hong Kong, Indonesia, India, Malaysia and the Philippines. Three years ago, Cordlife became a leading player in Hong Kong after it forked out US$7 million to acquire the largest private cord blood bank there, Healthbaby Biotech (Hong Kong) Co. Since then, there has been nothing on the M& A front.
The quiet is especially surprising since Cordlife had a cash hoard of S$73.2 million as at end-September 2021, which is more than 70 per cent of its current market value.
The big question now is: will the entry of a new controlling owner and the ensuing board shuffle, among others, be the driving force for growth that has long eluded Cordlife?
keep retreating. Haiz....
Cordlife Group
On Nov 10, TransGlobal Real Estate Group acquired 71,460,300 shares of Cordlife Cordlife: P8A -1.16% at 52.0 cents per share. The married deal, with a consideration of S$37,159,356, took TransGlobal' s direct interest in the regional pioneer of private cord blood banking to 27.99 per cent.
The acquisition saw the share price of Cordlife Group gain 15.3 per cent on Nov 10 to 49.0 cents, while achieving a session high of 53.5 cents, a level last seen in August 2019.
Cordlife Group substantial shareholders, Lui Yim Sheung and Yiu Chi Shing each hold 50 per cent of the voting rights of TransGlobal Real Estate Group. The shares were acquired from the former substantial shareholder, Hon Kwok Lung, and his nominee companies, Full Day and Sincere View International.
Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and is among the top three market leaders in India and Malaysia.
Big buyers have done their due when agreed to the married deal. So the valuation is clearly at least 52c. Storing of human body part for later use has endless potential and possiblity.
papayaface ( Date: 12-Nov-2021 05:54) Posted:
|
Here : https://www.nextinsight.net/story-archive-mainmenu-60/944-2021/14198-cordlife-stepping-up-as-expert-in-cryo-preservation-of-human-tissue
Gross profit margin at 63.3%. Net cash as of march 2021 is 73.9 mil. After the recent runup, market cap is only 108 mil. Basically buying the business for only 35 mil. Zero borrowings. Cash generative. Earnings hit by covid in 2020 but starting to pick up.
ckh002 ( Date: 12-Nov-2021 04:01) Posted:
|